The invention provides a substituted benzylaminopiperidine compounds that are useful in the treatment of gastrointestinal disorders; central nervous system (CNS) disorders; inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by Heliobacter pylori; or angiogenesis, especially CNS disorders in a mammalian subject, especially in humans.

The invention provides a compound of formula (I): ##STR1## and its pharmaceutically acceptable salts, wherein R is halo C.sub.2 -C.sub.8 alkenyl or halo C.sub.2 -C.sub.8 alkynyl; R.sup.1 is hydrogen, halo or C.sub.1 -C.sub.6 alkoxy; or R and R.sup.1, together with the two carbon atoms to which they are attached, form a C.sub.4 -C.sub.6 cycloalkyl or a C.sub.4 -C.sub.6 oxacycloalkyl ring wherein said ring may be optionally substituted by one or more substituents selected from the group consisting of halo, C.sub.1 -C.sub.6 alkyl and halo C.sub.1 -C.sub.6 alkyl; X is C.sub.1 -C.sub.6 alkoxy, halo C.sub.1 -C.sub.6 alkoxy, phenoxy or halo; and Ar is phenyl optionally substituted by halo. These compounds are useful in the treatment of a gastrointestinal disorder; a central nervous system (CNS) disorder; an inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans.

The present invention relates to a 5-phenylbenzylamine compound represented by the formula [1]: ##STR00001## wherein Ring A represents a phenyl group having a substituent(s), R.sup.a, R.sup.b1 and R.sup.b2 each represent hydrogen atom, a halogen atom, a lower alkyl group, a halogeno-lower alkyl group or a lower alkoxy group, R.sup.c1 represents hydrogen atom, a lower alkyl group optionally substituted by a heterocyclic group, or an acyl group, R.sup.c2 and R.sup.e each represent hydrogen atom or a lower alkyl group, R.sup.d represents hydrogen atom, a lower alkyl group or an acyl group, and R.sup.f represents a lower alkyl group or a cyclic lower alkyl group, or a pharmaceutically acceptable salt thereof, a process for preparing the same and synthetic intermediate thereof.

A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.

Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.